Insulin Aspart 300IU Pen

Premium HealthCare UK Insulin Aspart 300IU is a rapid-acting insulin analogue studied for postprandial glucose management and insulin receptor pharmacology research.

Key Details
– 300 IU insulin pen
– Subcutaneous injection via pen device

Research Benefits
– Rapid onset within 10 to 20 minutes
– Peak action at 1 to 3 hours post-injection
– Studied for postprandial glucose excursion research
– Insulin receptor signalling and anabolic pathway research
– Comparative pharmacokinetics versus regular human insulin

Suggested Research Protocol
– Dose: Research protocol and glucose monitoring dependent
– Administer 5 to 15 minutes before research meals

Quality Assurance: Pharmaceutical grade, batch verified.